LCZ696: a new paradigm for the treatment of heart failure?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

LCZ696: a new paradigm for the treatment of heart failure?

Published:2015-01-19 Issue:3 Volume:16 Page:435-446
ISSN:1465-6566
Container-title:Expert Opinion on Pharmacotherapy
language:en
Short-container-title:Expert Opinion on Pharmacotherapy

Author:

Minguet Joan¹²,Sutton Gemma¹,Ferrero Carmen³,Gomez Timothy¹,Bramlage Peter¹²³

Affiliation:

1. 1Institute for Research and Medicine Advancement (IRMEDICA), Barcelona, Spain

2. 2Institute for Pharmacology and Preventive Medicine, Menzelstrasse 21, 15831 Mahlow, Germany ; ;

3. 3University of Sevilla, Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, Sevilla, Spain

Publisher

Informa Healthcare

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1517/14656566.2015.1000300

Reference50 articles.

1. 2013 ACCF/AHA Guideline for the Management of Heart Failure

2. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012

3. Understanding the Epidemic of Heart Failure: Past, Present, and Future

4. Epidemiology and risk profile of heart failure

5. Epidemiology of Heart Failure

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessment of drug–drug interaction of dapagliflozin with LCZ696 based on an LC–MS/MS method;Biomedical Chromatography;2024-06-23

2. Sacubitril/valsartan reduces susceptibility to atrial fibrillation by improving atrial remodeling in spontaneously hypertensive rats;European Journal of Pharmacology;2023-08

3. End-Of-Life Care for Patients With End-Stage Heart Failure, Comparisons of International Guidelines;American Journal of Hospice and Palliative Medicine®;2023-01-27

4. Development and validation of UV spectroscopic method for estimation of sacubitril and valsartan combination (LCZ696) in bulk and pharmaceutical tablet dosage forms;Research Journal of Pharmacy and Technology;2022-11-24

5. Effect of Sacubitril/Valsartan on renal function in patients with chronic kidney disease and heart failure with preserved ejection fraction: A real-world 12-week study;European Journal of Pharmacology;2022-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3